Hepatitis and related syndromes may be a stronger predictor of early atherosclerosis than such classic risk factors as insulin resistance, according to Italian researchers.
Hepatitis and related syndromes may be a stronger predictor of early atherosclerosis than such classic risk factors as insulin resistance, according to Italian researchers.
Researchers, using carotid ultrasound, found high levels of early atherosclerosis in patients with nonalcoholic steatohepatitis and chronic hepatitis B and C independent of classic risk factors. Highest of all were the patients with nonalcoholic steatohepatitis, regardless of age, sex, smoking history, LDL cholesterol, or insulin resistance.
Giovanni Targher from the internal medicine division at Sacro Cuore Hospital in Negrar, Italy, and colleagues at the University Hospital of Verona studied 215 subjects. They used ultrasound to measure common carotid intima-media thickness, an index of early atherosclerosis on 60 consecutive patients with biopsy-proven nonalcoholic steatohepatitis, 60 with chronic hepatitis C, 35 with hepatitis B, and an additional 60 healthy controls of comparable age and sex. The ultrasound operator was blinded to subjects' characteristics.
The lowest carotid intima-media thickness measurements were in the controls, at an average of 0.84 mm. Measurements in patients with chronic hepatitis B averaged 0.97 mm, and measurements for patients with chronic hepatitis C averaging 1.09 mm. Highest of all were measurements in patients with nonalcoholic steatohepatitis at an average of 1.23 mm. Adjusting for age, sex, body mass index, smoking, LDL cholesterol, insulin resistance, and components of the Adult Treatment Panel III-defined metabolic syndrome had little effect on any group's measurements.
Ultrasound helped researchers conclude that nonalcoholic steatophepatitis and chronic hepatitis C and B are factors more strongly associated with early atherosclerosis than classic risk factors including insulin resistance and metabolic syndrome components.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Month, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.